ClinicalTrials HQ

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Recruiting · NCT05004129 · Registry updated 2025-05-28
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic DystrophyCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular diseaseRecruitingPhase 2 / Phase 32025-05-28NCT05004129

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
AMO Pharma Limited2

14 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Arkansas Children's HospitalLittle RockUnited States82
Children's Hospital London Health Sciences Centre (LHSC)LondonCanada1
Children's Hospital of Eastern OntarioOttawaCanada63
Children's Hospital of The King's DaughtersNorfolkUnited States87
Lurie's Children's HospitalChicagoUnited States1
New Zealand Clinical Research (NZCR)AucklandNew Zealand2
Stanford UniversityPalo AltoUnited States161
The Bright AllianceRandwickAustralia1
University of California, Los Angeles (UCLA)Los AngelesUnited States14
University of Iowa Hospitals and ClinicsIowa CityUnited States99
University of Pittsburgh Medical CenterPittsburghUnited States127
University of Rochester - Medical CenterRochesterUnited States1
University of Utah Clinical Neurosciences CenterSalt Lake CityUnited States6
Virginia Commonwealth University-Department of Neurology - Muscular Dystrophy Translational Research ProgramRichmondUnited States1